Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease.
ACE inhibitors
GLP-1 receptor agonists
SGLT2 inhibitors
albuminuria
angiotensin receptor blockers
cardiovascular disease
diabetic nephropathy
disparity
non-steroidal mineralocorticoid antagonist
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
pubmed:
2
6
2022
medline:
12
7
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Diabetic kidney disease is the most frequent cause of kidney failure, accounting for half of all cases worldwide. Moreover, deaths from diabetic kidney disease increased 106% between 1990 and 2013, with most attributed to cardiovascular disease. Recommended screening and monitoring for diabetic kidney disease are conducted in less than half of patients with diabetes. Standard-of-care treatment with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker is correspondingly low. Sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid antagonist are highly effective therapies to reduce kidney and cardiovascular risks in diabetic kidney disease. However, <20% of eligible patients are receiving these agents. Critical barriers are high out-of-pocket drug costs and low reimbursement rates. Data demonstrating clinical and cost-effectiveness of diabetic kidney disease care are needed to garner payer and health care system support. The pharmaceutical industry should collaborate on value-based care by increasing access through affordable drug prices. Additionally, multidisciplinary models and communication technologies tailored to individual health care systems are needed to support optimal diabetic kidney disease care. Community outreach efforts are also central to make care accessible and equitable. Finally, it is imperative that patient preferences and priorities shape implementation strategies. Access to care and implementation of breakthrough therapies for diabetic kidney disease can save millions of lives by preventing kidney failure, cardiovascular events, and premature death. Coalitions composed of patients, families, community groups, health care professionals, health care systems, federal agencies, and payers are essential to develop collaborative models that successfully address this major public health challenge.
Identifiants
pubmed: 35649722
pii: 01277230-202207000-00023
doi: 10.2215/CJN.02980322
pmc: PMC9269635
doi:
Substances chimiques
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Mineralocorticoid Receptor Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1092-1103Informations de copyright
Copyright © 2022 by the American Society of Nephrology.
Références
American Diabetes Association: 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2021 . Diabetes Care 44[Suppl 1]: S151–S167, 2021
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group: KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Available at: https://www.kidney-international.org/action/showPdf?pii=S0085-2538%2820%2930718-3. Accessed June 14, 2022
Centers for Disease Control and Prevention: National Diabetes Statistics Report. Available at: https://www.cdc.gov/diabetes/data/statistics-report/index.html . Accessed February 18, 2022
International Diabetes Federation: IDF Diabetes Atlas, 9th Ed., Brussels, Belgium, International Diabetes Federation, 2021
Alicic RZ, Rooney MT, Tuttle KR: Diabetic kidney disease: Challenges, progress, and possibilities. Clin J Am Soc Nephrol 12: 2032–2045, 2017
Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai CY, Floyd T, Al-Aly Z: Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 94: 567–581, 2018 10.1016/j.kint.2018.04.011
doi: 10.1016/j.kint.2018.04.011
United States Renal Data System: 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2021
Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW: Global trends in diabetes complications: A review of current evidence. Diabetologia 62: 3–16, 2019 10.1007/s00125-018-4711-2
doi: 10.1007/s00125-018-4711-2
Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L: Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 370: 1514–1523, 2014 10.1056/NEJMoa1310799
doi: 10.1056/NEJMoa1310799
Koye DN, Magliano DJ, Nelson RG, Pavkov ME: The global epidemiology of diabetes and kidney disease. Adv Chronic Kidney Dis 25: 121–132, 2018 10.1053/j.ackd.2017.10.011
doi: 10.1053/j.ackd.2017.10.011
GBD 2013 Mortality and Causes of Death Collaborators: Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 385: 117–171, 2015 10.1016/S0140-6736(14)61682-2
doi: 10.1016/S0140-6736(14)61682-2
Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ: Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: Results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 59: 75–83, 2012
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2017 update: A report from the American Heart Association. Circulation 135: e146–e603, 2017 10.1161/CIR.0000000000000485
doi: 10.1161/CIR.0000000000000485
Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, McPherson SM, Neumiller JJ, Bell DS, Mangione CM, Norris KC: Clinical characteristics of and risk factors for chronic kidney disease among adults and children: An analysis of the CURE-CKD Registry. JAMA Netw Open 2: e1918169, 2019 10.1001/jamanetworkopen.2019.18169
doi: 10.1001/jamanetworkopen.2019.18169
Alfego D, Ennis J, Gillespie B, Lewis MJ, Montgomery E, Ferrè S, Vassalotti JA, Letovsky S: Chronic kidney disease testing among at-risk adults in the U.S. remains low: Real-world evidence from a national laboratory database. Diabetes Care 44: 2025–2032, 2021 10.2337/dc21-0723
doi: 10.2337/dc21-0723
KDOQI: KDOQI clinical practice guidelines and clinical recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49[2 Suppl 2]: S12–S154, 2007
Murphy DP, Drawz PE, Foley RN: Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States. J Am Soc Nephrol 30: 1314–1321, 2019 10.1681/ASN.2018100971
doi: 10.1681/ASN.2018100971
Bullock A, Burrows NR, Narva AS, Sheff K, Hora I, Lekiachvili A, Cain H, Espey D: Vital signs: Decrease in incidence of diabetes-related end-stage renal disease among American Indians/Alaska Natives - United States, 1996-2013. MMWR Morb Mortal Wkly Rep 66: 26–32, 2017 10.15585/mmwr.mm6601e1
doi: 10.15585/mmwr.mm6601e1
Centers for Disease Control and Prevention. Available at: https://nccd.cdc.gov/CKD/. Accessed February 18, 2022
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383: 1436–1446, 2020 10.1056/NEJMoa2024816
doi: 10.1056/NEJMoa2024816
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators: Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383: 2219–2229, 2020 10.1056/NEJMoa2025845
doi: 10.1056/NEJMoa2025845
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators: Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385: 2252–2263, 2021 10.1056/NEJMoa2110956
doi: 10.1056/NEJMoa2110956
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL; FIDELIO-DKD and FIGARO-DKD investigators: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J 43: 474–484, 2022 10.1093/eurheartj/ehab777
doi: 10.1093/eurheartj/ehab777
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128, 2015 10.1056/NEJMoa1504720
doi: 10.1056/NEJMoa1504720
Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC: Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9: 653–662, 2021 10.1016/S2213-8587(21)00203-5
doi: 10.1016/S2213-8587(21)00203-5
Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, Botros FT: Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 6: 605–617, 2018 10.1016/S2213-8587(18)30104-9
doi: 10.1016/S2213-8587(18)30104-9
Harris ST, Patorno E, Zhuo M, Kim SC, Paik JM: Prescribing trends of antidiabetes medications in patients with type 2 diabetes and diabetic kidney disease, a cohort study. Diabetes Care 44: 2293–2301, 2021 10.2337/dc21-0529
doi: 10.2337/dc21-0529
Tuttle KR, Cherney DZ; Diabetic Kidney Disease Task Force of the American Society of Nephrology: Sodium glucose cotransporter 2 inhibition heralds a call-to-action for diabetic kidney disease. Clin J Am Soc Nephrol 15: 285–288, 2020 10.2215/CJN.07730719
doi: 10.2215/CJN.07730719
Kliger AS, Brosius FC; Diabetic Kidney Disease Task Force of the American Society of Nephrology: Preserving kidney function instead of replacing it. Clin J Am Soc Nephrol 15: 129–131, 2020 10.2215/CJN.07820719
doi: 10.2215/CJN.07820719
Brosius FC, Cherney D, Gee PO, Harris RC, Kliger AS, Tuttle KR, Quaggin SE; DKD-Collaborative ASN Taskforce: Transforming the care of patients with diabetic kidney disease. Clin J Am Soc Nephrol 16: 1590–1600, 2021 10.2215/CJN.18641120
doi: 10.2215/CJN.18641120
Patel RB, Al Rifai M, McEvoy JW, Vaduganathan M: Implications of specialist density for diabetes care in the United States. JAMA Cardiol 4: 1174–1175, 2019 10.1001/jamacardio.2019.3796
doi: 10.1001/jamacardio.2019.3796
Rangaswami J, Tuttle K, Vaduganathan M: Cardio-renal-metabolic care models: Toward achieving effective interdisciplinary care. Circ Cardiovasc Qual Outcomes 13: e007264, 2020 10.1161/CIRCOUTCOMES.120.007264
doi: 10.1161/CIRCOUTCOMES.120.007264
Neumiller JJ, Alicic RZ, Tuttle KR: Overcoming barriers to implementing new therapies for diabetic kidney disease: Lessons learned. Adv Chronic Kidney Dis 28: 318–327, 2021 10.1053/j.ackd.2021.02.001
doi: 10.1053/j.ackd.2021.02.001
Lawrence JM, Divers J, Isom S, Saydah S, Imperatore G, Pihoker C, Marcovina SM, Mayer-Davis EJ, Hamman RF, Dolan L, Dabelea D, Pettitt DJ, Liese AD; SEARCH for Diabetes in Youth Study Group: Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US, 2001-2017. JAMA 326: 717–727, 2021 10.1001/jama.2021.11165
doi: 10.1001/jama.2021.11165
Cioana M, Deng J, Hou M, Nadarajah A, Qiu Y, Chen SSJ, Rivas A, Banfield L, Chanchlani R, Dart A, Wicklow B, Alfaraidi H, Alotaibi A, Thabane L, Samaan MC: Prevalence of hypertension and albuminuria in pediatric type 2 diabetes: A systematic review and meta-analysis. JAMA Netw Open 4: e216069, 2021 10.1001/jamanetworkopen.2021.6069
doi: 10.1001/jamanetworkopen.2021.6069
McEwan P, Morgan AR, Boyce R, Bergenheim K, Gause-Nilsson IAM, Bhatt DL, Leiter LA, Johansson PA, Mosenzon O, Cahn A, Wilding JPH: The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes Obes Metab 23: 1020–1029, 2021 10.1111/dom.14308
doi: 10.1111/dom.14308
McEwan P, Bennett H, Khunti K, Wilding J, Edmonds C, Thuresson M, Wittbrodt E, Fenici P, Kosiborod M: Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes Obes Metab 22: 2364–2374, 2020 10.1111/dom.14162
doi: 10.1111/dom.14162
Reifsnider OS, Kansal AR, Wanner C, Pfarr E, Koitka-Weber A, Brand SB, Stargardter M, Wang C, Kuti E, Ustyugova A: Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: Findings based on the EMPA-REG OUTCOME Trial. Am J Kidney Dis 79: 796–806, 2022
RAND Health Care: Value-Based Payment and Health Care System Preparedness and Resilience. Report for the Office of the Assistant Secretary for Planning and Evaluation (ASPE) at the US Department of Health & Human Services, June 2021. Available at: https://aspe.hhs.gov/sites/default/files/2021-08/PR-A1249-1-v2_ASPE.pdf . Accessed February 18, 2022
Johnson DC, O’Donnell J, Pothen M, Nguyen V, Smith T: Framework for specialty value transformation: Perspectives from a commercial payer. Health Affairs , August 27, 2021. Available at: https://www.healthaffairs.org/do/10.1377/forefront.20210825.518146/full/ . Accessed February 18, 2022
Williams J: A more nuanced view of dialysis providers “gaming the rules.” AJMC , June 27, 2021. Available at: https://www.ajmc.com/view/contributor-a-more-nuanced-view-of-dialysis-providers-gaming-the-rules- . Accessed February 18, 2022
GoodRx: US retail drug prices. Available at: www.goodrx.com . Accessed April 11, 2022
The Medical Letter: Comparison Chart: Sodium glucose cotransporter 2 (SGLT2) inhibitors, May 17, 2021. Available at: https://secure.medicalletter.org/downloads/1611f_table.pdf. Accessed February 18, 2022
Robert Wood Johnson Foundation: In the Years Before the COVID-19 Pandemic, Nearly 13 Million Adults Delayed or Did Not Get Needed Prescription Drugs Because of Costs. Available at: https://www.rwjf.org/en/library/research/2021/11/in-the-years-before-the-covid-19-pandemic-nearly-13-million-adults-delayed-or-did-not-get-needed-prescription-drugs-because-of-cost.html. Accessed December 10, 2021
PharmacyChecker.com: US, Canadian, and international drug price comparisons. Available at: www.pharmacychecker.com . Accessed April 11, 2022
The Medical Letter: Prescription drug prices in the US, May 22, 2017. Available at: https://secure.medicalletter.org/TML-article-1521a. Accessed February 18, 2022
Czeisler ME, Barrett CE, Siegel KR, Weaver MD, Czeisler CA, Rajaratnam SMW, Howard ME, Bullard KM: Health care access and use among adults with diabetes during the COVID-19 pandemic—United States, February–March 2021. MMWR Morb Mortal Wkly Rep 70: 1597–1602, 2021 10.15585/mmwr.mm7046a2MWR
doi: 10.15585/mmwr.mm7046a2MWR
Cuffee YL, Hargraves JL, Rosal M, Briesacher BA, Schoenthaler A, Person S, Hullett S, Allison J: Reported racial discrimination, trust in physicians, and medication adherence among inner-city African Americans with hypertension. Am J Public Health 103: e55–e62, 2013 10.2105/AJPH.2013.301554
doi: 10.2105/AJPH.2013.301554
Kraft SA, Cho MK, Gillespie K, Halley M, Varsava N, Ormond KE, Luft HS, Wilfond BS, Soo-Jin Lee S: Beyond consent: Building trusting relationships with diverse populations in precision medicine research. Am J Bioeth 18: 3–20, 2018 10.1080/15265161.2018.1431322
doi: 10.1080/15265161.2018.1431322
Kim K, Choi JS, Choi E, Nieman CL, Joo JH, Lin FR, Gitlin LN, Han HR: Effects of community-based health worker interventions to improve chronic disease management and care among vulnerable populations: A systematic review. Am J Public Health 106: e3–e28, 2016 10.2105/AJPH.2015.302987
doi: 10.2105/AJPH.2015.302987
Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR: A unifying approach for GFR estimation: Recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. J Am Soc Nephrol 32: 2994–3015, 2021 10.1681/ASN.2021070988
doi: 10.1681/ASN.2021070988
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, Kalil R, Karger AB, Mauer M, Navis G, Nelson RG, Poggio ED, Rodby R, Rossing P, Rule AD, Selvin E, Seegmiller JC, Shlipak MG, Torres VE, Yang W, Ballew SH, Couture SJ, Powe NR, Levey AS; Chronic Kidney Disease Epidemiology Collaboration: New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 385: 1737–1749, 2021 10.1056/NEJMoa2102953
doi: 10.1056/NEJMoa2102953
Williams WW, Hogan JW, Ingelfinger JR: Time to eliminate health care disparities in the estimation of kidney function. N Engl J Med 385: 1804–1806, 2021 10.1056/NEJMe2114918
doi: 10.1056/NEJMe2114918
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group: KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9[Suppl 3]: S1–S155, 2009 10.1111/j.1600-6143.2009.02834.x
doi: 10.1111/j.1600-6143.2009.02834.x
Hariharan S, Israni AK, Danovitch G: Long-term survival after kidney transplantation. N Engl J Med 385: 729–743, 2021 10.1056/NEJMra2014530
doi: 10.1056/NEJMra2014530
Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B: Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes Obes Metab 21: 2192–2202, 2019 10.1111/dom.13811
doi: 10.1111/dom.13811